Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 185

Similar articles for PubMed (Select 18755984)

1.

Activating mutations in human acute megakaryoblastic leukemia.

Malinge S, Ragu C, Della-Valle V, Pisani D, Constantinescu SN, Perez C, Villeval JL, Reinhardt D, Landman-Parker J, Michaux L, Dastugue N, Baruchel A, Vainchenker W, Bourquin JP, Penard-Lacronique V, Bernard OA.

Blood. 2008 Nov 15;112(10):4220-6. doi: 10.1182/blood-2008-01-136366. Epub 2008 Aug 28.

2.

Functional analysis of JAK3 mutations in transient myeloproliferative disorder and acute megakaryoblastic leukaemia accompanying Down syndrome.

Sato T, Toki T, Kanezaki R, Xu G, Terui K, Kanegane H, Miura M, Adachi S, Migita M, Morinaga S, Nakano T, Endo M, Kojima S, Kiyoi H, Mano H, Ito E.

Br J Haematol. 2008 May;141(5):681-8. doi: 10.1111/j.1365-2141.2008.07081.x. Epub 2008 Apr 7.

PMID:
18397343
3.

Natural history of GATA1 mutations in Down syndrome.

Ahmed M, Sternberg A, Hall G, Thomas A, Smith O, O'Marcaigh A, Wynn R, Stevens R, Addison M, King D, Stewart B, Gibson B, Roberts I, Vyas P.

Blood. 2004 Apr 1;103(7):2480-9. Epub 2003 Dec 4.

4.

Molecular lesions in childhood and adult acute megakaryoblastic leukaemia.

Hama A, Muramatsu H, Makishima H, Sugimoto Y, Szpurka H, Jasek M, O'Keefe C, Takahashi Y, Sakaguchi H, Doisaki S, Shimada A, Watanabe N, Kato K, Kiyoi H, Naoe T, Kojima S, Maciejewski JP.

Br J Haematol. 2012 Feb;156(3):316-25. doi: 10.1111/j.1365-2141.2011.08948.x. Epub 2011 Nov 28.

PMID:
22122069
5.

Description of a novel Janus kinase 3 P132A mutation in acute megakaryoblastic leukemia and demonstration of previously reported Janus kinase 3 mutations in normal subjects.

Riera L, Lasorsa E, Bonello L, Sismondi F, Tondat F, Di Bello C, Di Celle PF, Chiarle R, Godio L, Pich A, Facchetti F, Ponzoni M, Marmont F, Zanon C, Bardelli A, Inghirami G.

Leuk Lymphoma. 2011 Sep;52(9):1742-50. doi: 10.3109/10428194.2011.574757. Epub 2011 May 23.

PMID:
21599579
6.

Loss-of-function JAK3 mutations in TMD and AMKL of Down syndrome.

De Vita S, Mulligan C, McElwaine S, Dagna-Bricarelli F, Spinelli M, Basso G, Nizetic D, Groet J.

Br J Haematol. 2007 May;137(4):337-41.

PMID:
17456055
7.

Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21.

Rainis L, Bercovich D, Strehl S, Teigler-Schlegel A, Stark B, Trka J, Amariglio N, Biondi A, Muler I, Rechavi G, Kempski H, Haas OA, Izraeli S.

Blood. 2003 Aug 1;102(3):981-6. Epub 2003 Mar 20.

8.

Acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: a multi-step model of myeloid leukaemogenesis.

Roy A, Roberts I, Norton A, Vyas P.

Br J Haematol. 2009 Oct;147(1):3-12. doi: 10.1111/j.1365-2141.2009.07789.x. Epub 2009 Jul 6. Review.

PMID:
19594743
9.

GATA1 as a new target to detect minimal residual disease in both transient leukemia and megakaryoblastic leukemia of Down syndrome.

Pine SR, Guo Q, Yin C, Jayabose S, Levendoglu-Tugal O, Ozkaynak MF, Sandoval C.

Leuk Res. 2005 Nov;29(11):1353-6.

PMID:
15916804
10.

Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder.

Cushing T, Clericuzio CL, Wilson CS, Taub JW, Ge Y, Reichard KK, Winter SS.

J Pediatr. 2006 May;148(5):687-9.

PMID:
16737888
11.

GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome.

Hitzler JK, Cheung J, Li Y, Scherer SW, Zipursky A.

Blood. 2003 Jun 1;101(11):4301-4. Epub 2003 Feb 13.

12.

GATA1 mutations in patients with down syndrome and acute megakaryoblastic leukaemia do not always confer a good prognosis.

Ariffin H, Garcia JC, Daud SS, Ibrahim K, Aizah N, Ong GB, Chong LA, Mohamad Z.

Pediatr Blood Cancer. 2009 Jul;53(1):108-11. doi: 10.1002/pbc.21983.

PMID:
19260099
13.

Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome.

Wechsler J, Greene M, McDevitt MA, Anastasi J, Karp JE, Le Beau MM, Crispino JD.

Nat Genet. 2002 Sep;32(1):148-52. Epub 2002 Aug 12.

PMID:
12172547
14.
15.

JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model.

Mercher T, Wernig G, Moore SA, Levine RL, Gu TL, Fröhling S, Cullen D, Polakiewicz RD, Bernard OA, Boggon TJ, Lee BH, Gilliland DG.

Blood. 2006 Oct 15;108(8):2770-9. Epub 2006 Jun 27.

16.

Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome.

Xu G, Nagano M, Kanezaki R, Toki T, Hayashi Y, Taketani T, Taki T, Mitui T, Koike K, Kato K, Imaizumi M, Sekine I, Ikeda Y, Hanada R, Sako M, Kudo K, Kojima S, Ohneda O, Yamamoto M, Ito E.

Blood. 2003 Oct 15;102(8):2960-8. Epub 2003 Jun 19.

17.

Review of the cytogenetic changes in acute megakaryoblastic leukemia: one disease or several?

Lu G, Altman AJ, Benn PA.

Cancer Genet Cytogenet. 1993 Jun;67(2):81-9.

PMID:
8330276
18.

Chromosome 7 abnormalities in acute megakaryoblastic leukemia associated with Down syndrome.

Kobayashi K, Usami I, Kubota M, Nishio T, Kakazu N.

Cancer Genet Cytogenet. 2005 Apr 15;158(2):184-7. Review.

PMID:
15796967
20.

A 15q24 microdeletion in transient myeloproliferative disease (TMD) and acute megakaryoblastic leukaemia (AMKL) implicates PML and SUMO3 in the leukaemogenesis of TMD/AMKL.

Haemmerling S, Behnisch W, Doerks T, Korbel JO, Bork P, Moog U, Hentze S, Grasshoff U, Bonin M, Rieß O, Janssen JW, Jauch A, Bartram CR, Reinhardt D, Koch KA, Bandapalli OR, Kulozik AE.

Br J Haematol. 2012 Apr;157(2):180-7. doi: 10.1111/j.1365-2141.2012.09028.x. Epub 2012 Feb 1.

PMID:
22296450
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk